Cardiol Therapeutics (CRDL) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Invivyd (IVVD) over the past year, losing 11.3% versus a loss of 83.5%. Over five years, CRDL leads with a -60.1% price change compared with -98.4% for IVVD. Invivyd is the larger company by market cap ($122.0 million vs $110.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | IVVD |
|---|---|---|
| Share price | $0.8626 | $0.4127 |
| Market cap | $110.14M | $122.01M |
| 1-day change | -2.28% | -7.45% |
| YTD return | -9.58% | -83.29% |
| 1-year return | -11.35% | -83.49% |
| 5-year return | -60.06% | -98.36% |
| EPS (TTM) | $-0.24 | $-0.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $53.43M |
| Revenue growth (YoY) | — | +110.47% |
| Net income (latest FY) | — | $-52.49M |
| Operating margin | — | -103.99% |
| Net margin | — | -98.25% |
| 52-week high | $2.34 | $3.01 |
| 52-week low | $0.8417 | $0.4127 |
| Distance from 52-week high | -63.14% | -86.29% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +874.96% | +2323.07% |
| Average volume | 1.20M | 5.20M |
| Shares outstanding | 127.69M | 295.63M |
| Employees | 18 | 122 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed IVVD by 72.1 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
CRDL vs IVVD FAQ
Which is bigger, Cardiol Therapeutics or Invivyd?
Invivyd (IVVD) is larger, with a market capitalization of $122.01M compared with $110.14M for Cardiol Therapeutics (CRDL).
Which stock has performed better over the past year, CRDL or IVVD?
CRDL returned -11.35% over the past 12 months, compared with -83.49% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Invivyd in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.